参考文献
|
-
Ahn, JS,Ahn, YC,Kim, JH(2015).Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.J Clin Oncol,33,2660-2666.
-
Antonia, SJ,Villegas, A,Daniel, D(2018).Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.N Engl J Med,379,2342-2350.
-
Antonia, SJ,Villegas, A,Daniel, D(2017).Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med,377,1919-1929.
-
Auperin, A,Le Pechoux, C,Rolland, E(2010).Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.J Clin Oncol,28,2181-2190.
-
Brahmer, J,Reckamp, KL,Baas, P(2015).Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.N Engl J Med,373,123-135.
-
Chen, YM(2020).First-line combination immunotherapy for metastatic non-small cell lung cancer.JCMA,83,433-441.
-
Faivre-Finn, C,Vicente, D,Kurata, T(2021).Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.J Thorac Oncol,16(5),860-867.
-
Gadgeel, S,Rodriguez-Abreu, D,Speranza, G(2020).Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.J Clin Oncol,38,1505-1517.
-
Gandhi, L,Rodriguez-Abreu, D,Gadgeel, S(2018).Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.N Engl J Med,378,2078-2092.
-
Gravara, LD,Battiloro, C,Cantile, R(2020).Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?.Lung Cancer Manag,9,LMT22.
-
Hanna, NH,Schneider, BJ,Temin, S(2020).Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.J Clin Oncol,38,1608-1632.
-
Hellmann, MD,Paz-Ares, L,Bernabe Caro, R(2019).Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.N Engl J Med,381,2020-2031.
-
Herbst, RS,Baas, P,Kim, DW(2016).Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet,387,1540-1550.
-
Herbst, RS,Giaccone, G,de Marinis, F(2020).Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.N Engl J Med,383,1328-1339.
-
Horn, L,Spigel, DR,Vokes, EE(2017).Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).J Clin Oncol,35,3924-3933.
-
Hui, R,Ozguroglu, M,Villegas, A(2019).Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.Lancet Oncol,20,1670-1680.
-
Murakami, S.(2019).Durvalumab for the treatment of non-small cell lung cancer.Expert Rev Anticancer Ther,19,1009-1016.
-
Pai-Scherf, L,Blumenthal, GM,Li, H(2017).FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.Oncologist,22,1392-1399.
-
Paz-Ares, L,Luft, A,Vicente, D(2018).Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.N Engl J Med,379,2040-2051.
-
Quaglia, MG,Farina, A,Bossu, E(1998).Human alpha1-glycoprotein acid as chiral selector in the enantioseparation of midodrine and deglymidodrine racemates by HPLC.J Pharm Biomed Anal,18,171-177.
-
Reck, M,Brahmer, J,Bennett, B(2018).Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.Eu J Cancer,102,23-30.
-
Reck, M,Rodriguez-Abreu, D,Robinson, AG(2019).Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.J Clin Oncol,37,537-546.
-
Reck, M,Rodriguez-Abreu, D,Robinson, AG(2016).Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.N Engl J Med,375,1823-1833.
-
Rittmeyer, A,Barlesi, F,Waterkamp, D(2017).Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Lancet,389,255-265.
-
Socinski, MA,Jotte, RM,Cappuzzo, F(2018).Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.N Engl J Med,378,2288-2301.
-
Vaddepally, RK,Kharel, P,Pandey, R(2020).Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.Cancers,12,738.
-
Vokes, EE,Ready, N,Felip, E(2018).Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.Annals of oncology : official journal of the European Society for Medical Oncology / ESMO,29,959-965.
|